|
|
Volumn 13, Issue 3, 2004, Pages 289-293
|
|
HEP DART 2003: Frontiers in drug development for viral hepatitis
|
|
Author keywords
Adefovir; Antiviral agents; BILN 2061; Clevudine; Entecavir; Genotypes; Hepatitis B virus; Hepatitis C virus; Interferon ; Isatoribine; Lamivudine; NM 283; Viramidine
|
|
Indexed keywords
ADEFOVIR DIPIVOXIL;
ALAMIFOVIR;
ANTIRETROVIRUS AGENT;
BENZIMIDAZOLE DERIVATIVE;
CILUPREVIR;
CLEVUDINE;
DIDANOSINE;
EMTRICITABINE;
ENTECAVIR;
GUANOSINE DERIVATIVE;
INTERFERON REGULATORY FACTOR 3;
ISATORIBINE;
LAMIVUDINE;
LIVER ENZYME;
NM 107;
PEGINTERFERON ALPHA2A;
PLACEBO;
PRODRUG;
PROTEINASE INHIBITOR;
RIBAMIDINE;
RIBAVIRIN;
RIBONUCLEOSIDE DERIVATIVE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SERINE PROTEINASE;
TELBIVUDINE;
TENOFOVIR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VALOPICITABINE;
VIRUS RNA;
ZIDOVUDINE;
BIOLOGICAL MODEL;
CLINICAL RESEARCH;
CLINICAL STUDY;
CLINICAL TRIAL;
COMORBIDITY;
CONFERENCE PAPER;
CROSS RESISTANCE;
DRUG BLOOD LEVEL;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG RESEARCH;
GENOTYPE;
HEART DISEASE;
HEPATITIS B VIRUS;
HEPATITIS C VIRUS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
INSULIN RESISTANCE;
LEADERSHIP;
LIVER DISEASE;
LIVER DYSFUNCTION;
MEDICAL INFORMATION;
NONHUMAN;
PATHOGENESIS;
PREVALENCE;
TREATMENT FAILURE;
TREATMENT PLANNING;
UNITED STATES;
VIRUS HEPATITIS;
VIRUS INHIBITION;
ANTIVIRAL AGENTS;
HEPACIVIRUS;
HEPATITIS A;
HEPATITIS A VIRUS, HUMAN;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS, VIRAL, HUMAN;
HUMANS;
TREATMENT OUTCOME;
|
|
EID: 1542708150
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.13.3.289 Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (1)
|
